Skip to main content

PROPIEDADES MECANICAS EMERGENTES DE PROTEINAS EN EL MIOCARDIO Y EN BIOMATERIALES CON APLICACIONES BIOTECNOLOGICAS

BIO2017-83640-P

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de I+D (Excelencia / Generación de Conocimiento)
Call year 2017
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III (F.S.P.)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Protein haploinsufficiency drivers identify MYBPC3 variants that cause hypertrophic cardiomyopathy

  • Suay-Corredera, Carmen
  • Pricolo, Maria Rosaria
  • Herrero-Galán, Elías
  • Velázquez-Carreras, Diana
  • Sánchez-Ortiz, David
  • García-Giustiniani, Diego
  • Delgado Blanco, Javier
  • Galano-Frutos, Juan José
  • García-Cebollada, Helena
  • Vilches, Silvia
  • Domínguez, Fernando
  • Sabater Molina, María
  • Barriales-Villa, Roberto
  • Frisso, Giulia
  • Sancho, Javier
  • Serrano Pubull, Luis, 1982-
  • García-Pavía, Pablo
  • Monserrat, Lorenzo
  • Alegre-Cebollada, Jorge
Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease. Variants in MYBPC3, the gene encoding cardiac myosin-binding protein C (cMyBP-C), are the leading cause of HCM. However, the pathogenicity status of hundreds of MYBPC3 variants found in patients remains unknown, as a consequence of our incomplete understanding of the pathomechanisms triggered by HCM-causing variants. Here, we examined 44 nontruncating MYBPC3 variants that we classified as HCM-linked or nonpathogenic according to cosegregation and population genetics criteria. We found that around half of the HCM-linked variants showed alterations in RNA splicing or protein stability, both of which can lead to cMyBP-C haploinsufficiency. These protein haploinsufficiency drivers associated with HCM pathogenicity with 100% and 94% specificity, respectively. Furthermore, we uncovered that 11% of nontruncating MYBPC3 variants currently classified as of uncertain significance in ClinVar induced one of these molecular phenotypes. Our strategy, which can be applied to other conditions induced by protein loss of function, supports the idea that cMyBP-C haploinsufficiency is a fundamental pathomechanism in HCM., J. A.-C. acknowledges funding from the Ministerio de Ciencia e Innovación (MCIN) through grants BIO2014-54768-P ; BIO2017-83640-P/MINECO/AEI/FEDER , UE; EIN2019-102966 and RYC-2014-16604 , the European Research Area Network on Cardiovascular Diseases (ERA-CVD/ ISCIII , Spain MINOTAUR, AC16/00045), and the Comunidad de Madrid (consortium Tec4Bio-CM, S2018/NMT-4443, FEDER). The CNIC is supported by the ISCIII, MCIN, and the Pro CNIC Foundation and was a Severo Ochoa Center of Excellence (SEV-2015-0505). We acknowledge funding from ISCIII to the Centro de Investigación Biomédica en Red (CB16/11/00425). L. S. acknowledges funding from MCIN (BFU2015-63571-P). J. S. acknowledges funding from AEI (PID2019-107293GB-I00), Gobierno de Aragón (E45_17R), and ERDF-InterregV-A POCTEFA, Spain (PIREPRED-EFA086/15). C. S.-C. is the recipient of an FPI-SO predoctoral fellowship BES-2016-076638. M. R. P. was the recipient of a PhD fellowship from the Italian Ministry of Education, Universities and Research , Italy. H. G.-C. is the recipient of an FPU16/04232 doctoral contract from MCIN.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Titin domains with reduced core hydrophobicity cause dilated cardiomyopathy

  • Martínez-Martín, Inés
  • Crousilles, Audrey
  • Ochoa, Juan Pablo
  • Velázquez-Carreras, Diana
  • Mortensen, Simon A.
  • Herrero-Galán, Elías
  • Delgado Blanco, Javier
  • Domínguez, Fernando
  • García-Pavía, Pablo
  • Sancho, David de
  • Wilmanns, Matthias
  • Alegre-Cebollada, Jorge
The underlying genetic defect in most cases of dilated cardiomyopathy (DCM), a common inherited heart disease, remains unknown. Intriguingly, many patients carry single missense variants of uncertain pathogenicity targeting the giant protein titin, a fundamental sarcomere component. To explore the deleterious potential of these variants, we first solved the wild-type and mutant crystal structures of I21, the titin domain targeted by pathogenic variant p.C3575S. Although both structures are remarkably similar, the reduced hydrophobicity of deeply buried position 3575 strongly destabilizes the mutant domain, a scenario supported by molecular dynamics simulations and by biochemical assays that show no disulfide involving C3575. Prompted by these observations, we have found that thousands of similar hydrophobicity-reducing variants associate specifically with DCM. Hence, our results imply that titin domain destabilization causes DCM, a conceptual framework that not only informs pathogenicity assessment of gene variants but also points to therapeutic strategies counterbalancing protein destabilization., J.A.-C. acknowledges funding from the Ministerio de Ciencia e Innovación (MCIN, MCIN/AEI/10.13039/501100011033) through grants BIO2017-83640-P (AEI/FEDER, EU), PID2020-120426GB-I00, and RED2022-134242-T and the Regional Government of Madrid (grant Tec4Bio S2018/NMT-4443, 50% co-financed by the European Social Fund and the European Regional Development Fund for the programming period 2014–2020). The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the MCIN, and the Pro CNIC Foundation and is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MCIN). I.M.-M. holds a fellowship from 'la Caixa' Foundation (ID 100010434, fellowship code LCF/BQ/DR20/11790009) and received support from a Erasmus + Training fellowship. Financial support to D.d.S. comes from Eusko Jaurlaritza (Basque Government) through the project IT1584-22 and from the MCIN through grants PID2021-127907NB-I00 (AEI/FEDER, UE) and RYC-2016-19590 (AEI/FSE, EU). We thank Maria Rosaria Pricolo for analysis support with database analysis, Vytautas Gapsys for his assistance using the pmx software package, and the staff at the DIPC Supercomputing Center and the Sample Preparation and Characterization facility of the EMBL Hamburg Unit for technical support. The synchrotron data were collected at beamline operated by EMBL Hamburg at the PETRA III storage ring (DESY, Hamburg, Germany). We thank the Spectroscopy and Nuclear Magnetic Resonance Core Unit at CNIO for access to CD instrumentation. Biorender.com was used as a source for icons included in some of the figures of this paper.
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Protein Haploinsufficiency Drivers Identify MYBPC3 Variants That Cause Hypertrophic Cardiomyopathy

  • Suay-Corredera, Carmen
  • Pricolo, María Rosaria
  • Herrero-Galán, Elías
  • Velázquez-Carreras, Diana
  • Sánchez-Ortiz, David
  • García-Giustiniani, Diego
  • Delgado, Javier
  • Galano-Frutos, Juan José
  • García-Cebollada, Helena
  • Vilches, Silvia
  • Domínguez, Fernando
  • Sabater Molina, María
  • Barriales-Villa, Roberto
  • Frisso, Giulia
  • Sancho, Javier
  • Serrano, Luis
  • García-Pavía, Pablo
  • Monserrat, Lorenzo
  • Alegre-Cebollada, Jorge
[Abstract] Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease. Variants in MYBPC3, the gene encoding cardiac myosin-binding protein C (cMyBP-C), are the leading cause of HCM. However, the pathogenicity status of hundreds of MYBPC3 variants found in patients remains unknown, as a consequence of our incomplete understanding of the pathomechanisms triggered by HCM-causing variants. Here, we examined 44 nontruncating MYBPC3 variants that we classified as HCM-linked or nonpathogenic according to cosegregation and population genetics criteria. We found that around half of the HCM-linked variants showed alterations in RNA splicing or protein stability, both of which can lead to cMyBP-C haploinsufficiency. These protein haploinsufficiency drivers associated with HCM pathogenicity with 100% and 94% specificity, respectively. Furthermore, we uncovered that 11% of nontruncating MYBPC3 variants currently classified as of uncertain significance in ClinVar induced one of these molecular phenotypes. Our strategy, which can be applied to other conditions induced by protein loss of function, supports the idea that cMyBP-C haploinsufficiency is a fundamental pathomechanism in HCM., J. A.-C. acknowledges funding from the Ministerio de Ciencia e Innovación (MCIN) through grants BIO2014-54768-P; BIO2017-83640-P/MINECO/AEI/FEDER, UE; EIN2019-102966 and RYC-2014-16604, the European Research Area Network on Cardiovascular Diseases (ERA-CVD/ISCIII, Spain MINOTAUR, AC16/00045), and the Comunidad de Madrid (consortium Tec4Bio-CM, S2018/NMT-4443, FEDER). The CNIC is supported by the ISCIII, MCIN, and the Pro CNIC Foundation and was a Severo Ochoa Center of Excellence (SEV-2015-0505). We acknowledge funding from ISCIII to the Centro de Investigación Biomédica en Red (CB16/11/00425). L. S. acknowledges funding from MCIN (BFU2015-63571-P). J. S. acknowledges funding from AEI (PID2019-107293GB-I00), Gobierno de Aragón (E45_17R), and ERDF-InterregV-A POCTEFA, Spain (PIREPRED-EFA086/15). C. S.-C. is the recipient of an FPI-SO predoctoral fellowship BES-2016-076638. M. R. P. was the recipient of a PhD fellowship from the Italian Ministry of Education, Universities and Research, Italy. H. G.-C. is the recipient of an FPU16/04232 doctoral contract from MCIN, Comunidad de Madrid; S2018/NMT-4443, Gobierno de Aragón; E45_17R, Gobierno de Aragón; EFA086/15
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A Network of Macrophages Supports Mitochondrial Homeostasis in the Heart

  • Nicolás-Ávila, José A.
  • Lechuga, Ana
  • Sanchez-Díaz, María
  • Díaz-García, Elena
  • Santiago, Demetrio J.
  • Rubio-Ponce, Andrea
  • LiangYao Li, Jackson
  • Balachander, Akhila
  • Quintana, Juan A.
  • Martínez de Mena, Raquel
  • Castejón-Vega, Beatriz
  • Pun-García, Andrés
  • Través, Paqui G.
  • Bonzón-Kulichenko, Elena
  • García-Marqués, Fernando
  • Cussó, Lorena
  • González, Noelia A.
  • González-Guerra, Andrés
  • Roche-Molina, Marta
  • Martin-Salamanca, Sandra
  • Crainiciuc, Georgiana
  • Guzmán, Gabriela
  • Larrazabal, Jagoba
  • Herrero-Galán, Elías
  • Alegre-Cebollada, Jorge
  • Lemke, Greg
  • Rothlin, Carla V.
  • Jiménez-Borreguero, Luis J.
  • Reyes, Guillermo
  • Castrillo, Antonio
  • Desco, Manuel
  • Muñoz-Cánoves, Pura
  • Ibáñez, Borja
  • Torres, Miguel
  • Guan Ng, Lai
  • Priori, Silvia G.
  • Bueno, Héctor
  • Vázquez, Jesús
  • Cordero, Mario D.
  • Bernal, Juan
  • Enríquez, José Antonio
  • Hidalgo, Andrés
Cardiomyocytes are subjected to the intense mechanical stress and metabolic demands of the beating heart. It is unclear whether these cells, which are long-lived and rarely renew, manage to preserve homeostasis on their own. While analyzing macrophages lodged within the healthy myocardium, we discovered that they actively took up material, including mitochondria, derived from cardiomyocytes. Cardiomyocytes ejected dysfunctional mitochondria and other cargo in dedicated membranous particles reminiscent of neural exophers, through a process driven by the cardiomyocyte's autophagy machinery that was enhanced during cardiac stress. Depletion of cardiac macrophages or deficiency in the phagocytic receptor Mertk resulted in defective elimination of mitochondria from the myocardial tissue, activation of the inflammasome, impaired autophagy, accumulation of anomalous mitochondria in cardiomyocytes, metabolic alterations, and ventricular dysfunction. Thus, we identify an immune-parenchymal pair in the murine heart that enables transfer of unfit material to preserve metabolic stability and organ function. Video Abstract: [Figure presented] A system of macrophages in the heart supports cardiomyocyte health by phagocytosing exopher particles ejected from cardiomyocytes that contain defective mitochondria, among other cellular contents., This study was supported by Intramural grants from the Severo Ochoa program (IGP-SO); grants SAF2015-71878-REDT and SAF2014-56819-R from the Ministerio de Ciencia e Innovacion (MICINN) to A.C.; European Research Council grant EU-rhythmy (ERC-ADG-2014-ID:669387) to S.G.P., and MATRIX (ERC-COG-2018-ID: 819775) to B.I.; L.G.N. is supported by SIgN core funding from A∗STAR; grant BFU2016-75144-R from the Ministry of Science and Innovation to J.A.B,; grants PGC2018-096486-B-I00 and RD16/0011/0019 (ISCIII) from MICINN, TNE-17CVD04 from the Leducq Foundation, and S2017/BMD-3875 from the Comunidad de Madrid to M.T; intramural grant TPC/O-SO and grants SAF2015-65633-R, RTI2018-099357-B-I00, and HFSP (RGP0016/2018) to J.A.E.; intramural grant IGP-SO to J.A.-C. and A.H.; BIO2017-83640-P and RYC-2014-16604 to J.A-C; grants PRB3 (IPT17/0019-ISCIII-SGEFI/ERDF, ProteoRed) from the Carlos III Institute of Health and Fondo de Investigaciones Sanitarias, BIO2015-67580-P and PGC2018-097019-B-I00 from MICINN to J.V.; RTI2018-096068 from MICINN, AFM, MDA, LaCaixa-HR17-00040, UPGRADE-H2020-825825, and European Research Council (ERC-741538) to P.M.C.; S2017/BMD-3867 RENIM-CM from the Comunidad de Madrid and cofunded with European structural and investment funds to M.D.; 120/C/2015-20153032 from Fundació la Marató de TV3, SAF2015-65607-R and RTI2018-095497-B-I00 from MICINN, HR17_00527 from La Caixa Foundation, and TNE-18CVD04 from the Leducq Foundation to A.H.; C.V.R. is a Howard Hughes Medical Institute Faculty Scholar; J.A.N-A is supported by fellowship SVP-2014-068595, A.V.L.-V. by SVP-2013-068089, L.E.-M. by FJCI-2016-29384, and A.R.-P. by BES-2016-076635, all from MICINN; and the CNIC International Postdoctoral Program (EU grant agreement 600396 to D.J.S.). The CNIC is supported by the MICINN and the Pro-CNIC Foundation and is a Severo Ochoa Center of Excellence (MICINN award SEV-2015-0505).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Protein haploinsufficiency drivers identify MYBPC3 variants that cause hypertrophic cardiomyopathy

  • Suay-Corredera, Carmen
  • Pricolo, Maria Rosaria
  • Herrero-Galán, Elías
  • Velázquez-Carreras, Diana
  • Sánchez-Ortiz, David
  • García-Giustiniani, Diego
  • Delgado, Javier
  • Galano-Frutos, Juan J.
  • García-Cebollada, Helena
  • Vilches, S.
  • Domínguez, Fernando
  • Sabater Molina, María
  • Barriales-Villa, Roberto
  • Frisso, Giulia
  • Sancho, Javier
  • Serrano, Luis
  • García-Pavía, Pablo
  • Monserrat, Lorenzo
  • Alegre Cebollada, Jorge
14 pags. 5 figs., 2 tabs., Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease. Variants in MYBPC3, the gene encoding cardiac myosin-binding protein C (cMyBP-C), are the leading cause of HCM. However, the pathogenicity status of hundreds of MYBPC3 variants found in patients remains unknown, as a consequence of our incomplete understanding of the pathomechanisms triggered by HCM-causing variants. Here, we examined 44 nontruncating MYBPC3 variants that we classified as HCM-linked or nonpathogenic according to cosegregation and population genetics criteria. We found that around half of the HCM-linked variants showed alterations in RNA splicing or protein stability, both of which can lead to cMyBP-C haploinsufficiency. These protein haploinsufficiency drivers associated with HCM pathogenicity with 100% and 94% specificity, respectively. Furthermore, we uncovered that 11% of nontruncating MYBPC3 variants currently classified as of uncertain significance in ClinVar induced one of these molecular phenotypes. Our strategy, which can be applied to other conditions induced by protein loss of function, supports the idea that cMyBP-C haploinsufficiency is a fundamental pathomechanism in HCM., . A.-C. acknowledges funding from the Ministerio de Ciencia e Innovación (MCIN) throughgrants BIO2014-54768-P; BIO2017-83640-P/MINECO/AEI/FEDER, UE; EIN2019-102966 and RYC-2014-16604, the European Research Area Network on Cardiovascular Diseases (ERA-CVD/ISCIII, Spain MINOTAUR, AC16/00045), and the Comunidad de Madrid (consortium Tec4Bio-CM, S2018/NMT-4443, FEDER). TheCNIC is supported by the ISCIII, MCIN, and the Pro CNIC Foundation and was a Severo Ochoa Center of Excellence (SEV-2015-0505). We acknowledge funding from ISCIII to the Centro de Investigación Biomédica en Red (CB16/11/00425). L. S. acknowl-edges funding from MCIN (BFU2015-63571-P). J. S. acknowledgesfunding from AEI (PID2019-107293GB-I00), Gobierno de Aragón(E45_17R), and ERDF-InterregV-A POCTEFA, Spain (PIREPRED-EFA086/15). C. S.-C. is the recipient of an FPI-SO predoctoral fellowship BES-2016-076638. M. R. P. was the recipient of a Ph D fellowship from the Italian Ministry of Education, Universities and Research, Italy. H. G.-C. is the recipient of an FPU16/04232 doctoralcontract from MCIN.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Computational modelling of the mechanical behaviour of protein-based hydrogels

  • Pérez-Benito, Ángela
  • Huerta-López, Carla
  • Alegre-Cebollada, Jorge
  • García-Aznar, José Manuel
  • Hervas-Raluy, Silvia
Protein-based hydrogels have been extensively studied in the field of biomaterials given their ability to mimic living tissues and their special resemblance to the extracellular matrix. Despite this, the methods used for the control of mechanical properties of hydrogels are very limited, focusing mainly on their elasticity, with an often unrealistic characterization of mechanical properties such as extensibility, stiffness and viscoelasticity. Being able to control these properties is essential for the development of new biomaterials, since it has been demonstrated that mechanical properties affect cell behaviour and biological processes. To better understand the mechanical behaviour of these biopolymers, a computational model is here developed to characterize the mechanical behaviour of two different protein-based hydrogels. Strain–stress tests and stress-relaxation tests are evaluated computationally and compared to the results obtained experimentally in a previous work. To achieve this goal the Finite Element Method is used, combining hyperelastic and viscoelastic models. Different hyperelastic constitutive models (Mooney–Rivlin, Neo-Hookean, first and third order Ogden, and Yeoh) are proposed to estimate the mechanical properties of the protein-based hydrogels by least-square fitting of the in-vitro uniaxial test results. Among these models, the first order Ogden model with a viscoelastic model defined in Prony parameters better reproduces the strain–stress response and the change of stiffness with strain observed in the in-vitro tests.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Titin domains with reduced core hydrophobicity cause dilated cardiomyopathy

  • Martínez-Martín, Inés
  • Crousilles, Audrey
  • Ochoa, Juan Pablo
  • Velázquez-Carreras, Diana
  • Mortensen, Simon A.
  • Herrero-Galán, Elías
  • Delgado Blanco, Javier
  • Domínguez, Fernando
  • García-Pavía, Pablo
  • Sancho, David de
  • Wilmanns, Matthias
  • Alegre-Cebollada, Jorge
The underlying genetic defect in most cases of dilated cardiomyopathy (DCM), a common inherited heart disease, remains unknown. Intriguingly, many patients carry single missense variants of uncertain pathogenicity targeting the giant protein titin, a fundamental sarcomere component. To explore the deleterious potential of these variants, we first solved the wild-type and mutant crystal structures of I21, the titin domain targeted by pathogenic variant p.C3575S. Although both structures are remarkably similar, the reduced hydrophobicity of deeply buried position 3575 strongly destabilizes the mutant domain, a scenario supported by molecular dynamics simulations and by biochemical assays that show no disulfide involving C3575. Prompted by these observations, we have found that thousands of similar hydrophobicity-reducing variants associate specifically with DCM. Hence, our results imply that titin domain destabilization causes DCM, a conceptual framework that not only informs pathogenicity assessment of gene variants but also points to therapeutic strategies counterbalancing protein destabilization., J.A.-C. acknowledges funding from the Ministerio de Ciencia e Innovación (MCIN, MCIN/AEI/10.13039/501100011033) through grants BIO2017-83640-P (AEI/FEDER, EU), PID2020-120426GB-I00, and RED2022-134242-T and the Regional Government of Madrid (grant Tec4Bio S2018/NMT-4443, 50% co-financed by the European Social Fund and the European Regional Development Fund for the programming period 2014–2020). The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the MCIN, and the Pro CNIC Foundation and is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MCIN). I.M.-M. holds a fellowship from 'la Caixa' Foundation (ID 100010434, fellowship code LCF/BQ/DR20/11790009) and received support from a Erasmus + Training fellowship. Financial support to D.d.S. comes from Eusko Jaurlaritza (Basque Government) through the project IT1584-22 and from the MCIN through grants PID2021-127907NB-I00 (AEI/FEDER, UE) and RYC-2016-19590 (AEI/FSE, EU). We thank Maria Rosaria Pricolo for analysis support with database analysis, Vytautas Gapsys for his assistance using the pmx software package, and the staff at the DIPC Supercomputing Center and the Sample Preparation and Characterization facility of the EMBL Hamburg Unit for technical support. The synchrotron data were collected at beamline operated by EMBL Hamburg at the PETRA III storage ring (DESY, Hamburg, Germany). We thank the Spectroscopy and Nuclear Magnetic Resonance Core Unit at CNIO for access to CD instrumentation. Biorender.com was used as a source for icons included in some of the figures of this paper.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Protein haploinsufficiency drivers identify MYBPC3 variants that cause hypertrophic cardiomyopathy

  • Suay-Corredera, Carmen
  • Pricolo, Maria Rosaria
  • Herrero-Galán, Elías
  • Velázquez-Carreras, Diana
  • Sánchez-Ortiz, David
  • García-Giustiniani, Diego
  • Delgado Blanco, Javier
  • Galano-Frutos, Juan José
  • García-Cebollada, Helena
  • Vilches, Silvia
  • Domínguez, Fernando
  • Sabater Molina, María
  • Barriales-Villa, Roberto
  • Frisso, Giulia
  • Sancho, Javier
  • Serrano Pubull, Luis, 1982-
  • García-Pavía, Pablo
  • Monserrat, Lorenzo
  • Alegre-Cebollada, Jorge
Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease. Variants in MYBPC3, the gene encoding cardiac myosin-binding protein C (cMyBP-C), are the leading cause of HCM. However, the pathogenicity status of hundreds of MYBPC3 variants found in patients remains unknown, as a consequence of our incomplete understanding of the pathomechanisms triggered by HCM-causing variants. Here, we examined 44 nontruncating MYBPC3 variants that we classified as HCM-linked or nonpathogenic according to cosegregation and population genetics criteria. We found that around half of the HCM-linked variants showed alterations in RNA splicing or protein stability, both of which can lead to cMyBP-C haploinsufficiency. These protein haploinsufficiency drivers associated with HCM pathogenicity with 100% and 94% specificity, respectively. Furthermore, we uncovered that 11% of nontruncating MYBPC3 variants currently classified as of uncertain significance in ClinVar induced one of these molecular phenotypes. Our strategy, which can be applied to other conditions induced by protein loss of function, supports the idea that cMyBP-C haploinsufficiency is a fundamental pathomechanism in HCM., J. A.-C. acknowledges funding from the Ministerio de Ciencia e Innovación (MCIN) through grants BIO2014-54768-P ; BIO2017-83640-P/MINECO/AEI/FEDER , UE; EIN2019-102966 and RYC-2014-16604 , the European Research Area Network on Cardiovascular Diseases (ERA-CVD/ ISCIII , Spain MINOTAUR, AC16/00045), and the Comunidad de Madrid (consortium Tec4Bio-CM, S2018/NMT-4443, FEDER). The CNIC is supported by the ISCIII, MCIN, and the Pro CNIC Foundation and was a Severo Ochoa Center of Excellence (SEV-2015-0505). We acknowledge funding from ISCIII to the Centro de Investigación Biomédica en Red (CB16/11/00425). L. S. acknowledges funding from MCIN (BFU2015-63571-P). J. S. acknowledges funding from AEI (PID2019-107293GB-I00), Gobierno de Aragón (E45_17R), and ERDF-InterregV-A POCTEFA, Spain (PIREPRED-EFA086/15). C. S.-C. is the recipient of an FPI-SO predoctoral fellowship BES-2016-076638. M. R. P. was the recipient of a PhD fellowship from the Italian Ministry of Education, Universities and Research , Italy. H. G.-C. is the recipient of an FPU16/04232 doctoral contract from MCIN.